New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:31 EDTNBSNeoStem announces access to new $30M equity facility
NeoStem announced that it has filed today with the U.S. Securities and Exchange Commission a prospectus supplement to its shelf registration statement enabling it to access its new equity facility with Aspire Capital Fund which replaced the prior agreement under which the company received the full $20M in equity funding. Under the new agreement, NeoStem has the right to sell up to $30M in shares of common stock to Aspire Capital subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the company with additional capital and flexibility. As of the March 31, the company had approximately $41M of cash and cash equivalents available to fund operations.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
07:33 EDTNBSNeoStem receives drug manufacture license for Irvine, CA facility
NeoStem announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
January 12, 2015
07:47 EDTNBSNeoStem, Invetech agree to develop closed processing system
NeoStem and Invetech announced an agreement for the development of a new closed processing system for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use